genome-& ai-informed individualized care of infants in icus · rapid wes nsight2,...
TRANSCRIPT
![Page 1: Genome-& AI-Informed Individualized Care of infants in ICUs · Rapid WES NSIGHT2, ClinicalTrials.gov ID NCT03211039. 2019 status of rWGS-based individualized medicine for NICU and](https://reader030.vdocuments.mx/reader030/viewer/2022040313/5e09949b49340d224471f04a/html5/thumbnails/1.jpg)
Genome- & AI-Informed Individualized Care of infants in ICUsStephen Kingsmore, MD DSc
![Page 2: Genome-& AI-Informed Individualized Care of infants in ICUs · Rapid WES NSIGHT2, ClinicalTrials.gov ID NCT03211039. 2019 status of rWGS-based individualized medicine for NICU and](https://reader030.vdocuments.mx/reader030/viewer/2022040313/5e09949b49340d224471f04a/html5/thumbnails/2.jpg)
I do not have a conflict of interest with regard to this presentation
![Page 3: Genome-& AI-Informed Individualized Care of infants in ICUs · Rapid WES NSIGHT2, ClinicalTrials.gov ID NCT03211039. 2019 status of rWGS-based individualized medicine for NICU and](https://reader030.vdocuments.mx/reader030/viewer/2022040313/5e09949b49340d224471f04a/html5/thumbnails/3.jpg)
Discharged home undiagnosed
Delayed palliative care
Unnecessary morbidity and mortality
Delayed diagnosis; anxiety, suffering
Unnecessary Cost
• 15% of 250,000 US NICU and PICU infants have 1 of 14,000 genetic diseases
• 60% go undiagnosed and ∴ are mistreated; leading cause of death
55% Disease ofUnknown Etiology
Interim empirical treatment
Improvement or worsening
Treatment Modification
Search for etiological diagnosis
Genetic Testing 6+ weeks
NSIGHT2, ClinicalTrials.gov ID NCT03211039, 213 enrollees, 47% of NICU, 15% incidence
Infants in NICUs & PICUs
![Page 4: Genome-& AI-Informed Individualized Care of infants in ICUs · Rapid WES NSIGHT2, ClinicalTrials.gov ID NCT03211039. 2019 status of rWGS-based individualized medicine for NICU and](https://reader030.vdocuments.mx/reader030/viewer/2022040313/5e09949b49340d224471f04a/html5/thumbnails/4.jpg)
![Page 5: Genome-& AI-Informed Individualized Care of infants in ICUs · Rapid WES NSIGHT2, ClinicalTrials.gov ID NCT03211039. 2019 status of rWGS-based individualized medicine for NICU and](https://reader030.vdocuments.mx/reader030/viewer/2022040313/5e09949b49340d224471f04a/html5/thumbnails/5.jpg)
Evolution of Individualized Medicine in Children’s ICUs
$2.7 Billion
13 years
2003
1st Genome
Nature 460: 1011
1st Medical Genome
$2 Million
1.5 years
2009
Sci. Transl. Med. 4:154ra135
1st GenerationResearchPrototype
$13,00050
hours
2012
Lancet RespirMed. 3:377
1st ClinicalUtility Study;
2nd
GenerationTest
2015
$13,00026
hours
1st
EffectivenessStudy;
3rd
GenerationTest
npj Genomic Medicine 3:10
2018
$8,50019
hours
![Page 6: Genome-& AI-Informed Individualized Care of infants in ICUs · Rapid WES NSIGHT2, ClinicalTrials.gov ID NCT03211039. 2019 status of rWGS-based individualized medicine for NICU and](https://reader030.vdocuments.mx/reader030/viewer/2022040313/5e09949b49340d224471f04a/html5/thumbnails/6.jpg)
Two Early Studies of Clinical Utility of rWGS-based Individualized Medicine
(before individualized medicine mentoring)
Lancet Respir Med (2015) 3:377 npj Genomic Med (2018 3:6)
rWGS + Standard Testing
Time to Diagnosis (days)
Prop
ortio
n D
iagn
osed
Standard Testing
![Page 7: Genome-& AI-Informed Individualized Care of infants in ICUs · Rapid WES NSIGHT2, ClinicalTrials.gov ID NCT03211039. 2019 status of rWGS-based individualized medicine for NICU and](https://reader030.vdocuments.mx/reader030/viewer/2022040313/5e09949b49340d224471f04a/html5/thumbnails/7.jpg)
Two Recent Studies of Effectiveness of rWGS-based Individualized Medicine
npj Genomic Medicine (2018) 3:10
Time from blood sample receipt to diagnosis Ultra-rapid WGS
Days
Rapid WGSRapid WES
NSIGHT2, ClinicalTrials.gov ID NCT03211039
![Page 8: Genome-& AI-Informed Individualized Care of infants in ICUs · Rapid WES NSIGHT2, ClinicalTrials.gov ID NCT03211039. 2019 status of rWGS-based individualized medicine for NICU and](https://reader030.vdocuments.mx/reader030/viewer/2022040313/5e09949b49340d224471f04a/html5/thumbnails/8.jpg)
2019 status of rWGS-based individualized medicine for NICU and PICU Infants
55% Disease ofUnknown Etiology
Interim empirical treatment
25% Individualized
Medicine
Search for etiological
diagnosis inc.rWGS
20% improved outcomesLess cost & suffering
35% Genetic Disease
Diagnosis
rWGS 1.5-10 days
Infants in NICUs & PICUs
![Page 9: Genome-& AI-Informed Individualized Care of infants in ICUs · Rapid WES NSIGHT2, ClinicalTrials.gov ID NCT03211039. 2019 status of rWGS-based individualized medicine for NICU and](https://reader030.vdocuments.mx/reader030/viewer/2022040313/5e09949b49340d224471f04a/html5/thumbnails/9.jpg)
1%
Use
of r
WG
S in
unD
xN
ICU
, PIC
U in
fant
s
Barriersto
adoption
0% 25%
• Capital & labor intensity of individualizedmedicine
• rWGS and rWES methods are too slow to guideNICU and PICU management
• rWGS and rWES methods not scalable• Shortage of expert medical geneticists,
laboratory directors, genetic counselors• Lack of clinician familiarity with individualized
medicine• Shortage of expert medical geneticists, genetic
counselors• Insufficient evidence of efficacy
• Absence of reimbursement• Many genetic diseases lack effective Rx
• Most treatments lack adequate evidence
Barriers to Adoption of rWGS-based individualized medicine for NICU and PICU infants
2012 2018 2021
![Page 10: Genome-& AI-Informed Individualized Care of infants in ICUs · Rapid WES NSIGHT2, ClinicalTrials.gov ID NCT03211039. 2019 status of rWGS-based individualized medicine for NICU and](https://reader030.vdocuments.mx/reader030/viewer/2022040313/5e09949b49340d224471f04a/html5/thumbnails/10.jpg)
1%
Use
of r
WG
S in
unD
xN
ICU
, PIC
U in
fant
s
Barriersto
adoption
0% 25%
• Capital & labor intensity of individualizedmedicine
• rWGS and rWES methods are too slow to guideNICU and PICU management
• rWGS and rWES methods not scalable• Shortage of expert medical geneticists,
laboratory directors, genetic counselors• Lack of clinician familiarity with individualized
medicine• Shortage of expert medical geneticists, genetic
counselors• Insufficient evidence of efficacy
• Absence of reimbursement• Many genetic diseases lack effective Rx
• Most treatments lack adequate evidence
Barriers to Adoption of rWGS-based individualized medicine for NICU and PICU infants
2012 2018 2021
![Page 11: Genome-& AI-Informed Individualized Care of infants in ICUs · Rapid WES NSIGHT2, ClinicalTrials.gov ID NCT03211039. 2019 status of rWGS-based individualized medicine for NICU and](https://reader030.vdocuments.mx/reader030/viewer/2022040313/5e09949b49340d224471f04a/html5/thumbnails/11.jpg)
3rd generation whole genome sequencing with automated genetic disease diagnosis
Median time to result 20 hours; In Press
![Page 12: Genome-& AI-Informed Individualized Care of infants in ICUs · Rapid WES NSIGHT2, ClinicalTrials.gov ID NCT03211039. 2019 status of rWGS-based individualized medicine for NICU and](https://reader030.vdocuments.mx/reader030/viewer/2022040313/5e09949b49340d224471f04a/html5/thumbnails/12.jpg)
17 month old boy with fever (Tmax 1030F) x 3 days, vomiting, diarrhea, abdominal pain, labored breathing, skin lesions x 1 day
![Page 13: Genome-& AI-Informed Individualized Care of infants in ICUs · Rapid WES NSIGHT2, ClinicalTrials.gov ID NCT03211039. 2019 status of rWGS-based individualized medicine for NICU and](https://reader030.vdocuments.mx/reader030/viewer/2022040313/5e09949b49340d224471f04a/html5/thumbnails/13.jpg)
• Blood tests:• Metabolic panel: metabolic acidosis• C-reactive protein: markedly elevated• Complete blood count: low white cell count
• Abdominal ultrasound & computed tomography: No intussusception, possible mild colitis
• Lumbar puncture• Cardiovascular decompensation = hypovolemic shock → intravenous
fluids• SiO2 88% on Fi02 21% → Continuous Positive Airway Pressure ventilation• Sepsis suspected → intravenous vancomycin + ceftriaxone• Admitted to PICU → switched to intravenous meropenem
Rady Emergency Department Work Up
![Page 14: Genome-& AI-Informed Individualized Care of infants in ICUs · Rapid WES NSIGHT2, ClinicalTrials.gov ID NCT03211039. 2019 status of rWGS-based individualized medicine for NICU and](https://reader030.vdocuments.mx/reader030/viewer/2022040313/5e09949b49340d224471f04a/html5/thumbnails/14.jpg)
• Blood culture: Pseudomonas aeruginosa• Skin rash diagnosed as echthyma gangrenosum• Rapid genome sequencing ordered
Hospital Day 2
![Page 15: Genome-& AI-Informed Individualized Care of infants in ICUs · Rapid WES NSIGHT2, ClinicalTrials.gov ID NCT03211039. 2019 status of rWGS-based individualized medicine for NICU and](https://reader030.vdocuments.mx/reader030/viewer/2022040313/5e09949b49340d224471f04a/html5/thumbnails/15.jpg)
Step 1: Order in Epic Electronic Health Record
Yes
Pseudomonal sepsis, leukopenia
![Page 16: Genome-& AI-Informed Individualized Care of infants in ICUs · Rapid WES NSIGHT2, ClinicalTrials.gov ID NCT03211039. 2019 status of rWGS-based individualized medicine for NICU and](https://reader030.vdocuments.mx/reader030/viewer/2022040313/5e09949b49340d224471f04a/html5/thumbnails/16.jpg)
• 0.5 ml blood, dried blood spot• Illumina Nextera Flex
Step 2: Genome library preparation (2.5 hours)
Fragmentation
5 cycles PCR amplification
![Page 17: Genome-& AI-Informed Individualized Care of infants in ICUs · Rapid WES NSIGHT2, ClinicalTrials.gov ID NCT03211039. 2019 status of rWGS-based individualized medicine for NICU and](https://reader030.vdocuments.mx/reader030/viewer/2022040313/5e09949b49340d224471f04a/html5/thumbnails/17.jpg)
• 2 x 100 nucleotide paired sequences
• Illumina NovaSeq 6000 instrument
• S1 flowcell• Trio or 2 Probands per
flowcell• 40X proband; 30X parents
Step 3: Genome Sequencing (15.5 hours)
![Page 18: Genome-& AI-Informed Individualized Care of infants in ICUs · Rapid WES NSIGHT2, ClinicalTrials.gov ID NCT03211039. 2019 status of rWGS-based individualized medicine for NICU and](https://reader030.vdocuments.mx/reader030/viewer/2022040313/5e09949b49340d224471f04a/html5/thumbnails/18.jpg)
Step 4: Identify all disease-causing variants in child’s genome: 45 min
125 billion nucleotides sequenced
2.8 billion genomic nucleotides assigned
4.9 million variants identified & genotyped
Illumina DRAGEN 2.0
125 billion nucleotides sequenced
2.8 billion genomic nucleotides assigned
4.9 million variants identified & genotyped
125 billion nucleotides sequenced
2.8 billion genomic nucleotides assigned
4.9 million variants identified & genotyped
Glossary: Nucleotide – a single DNA letter (base); Adenine, Cytosine, Guanine or Thymidine
Variant – a DNA change from the (normal) reference genome sequence
![Page 19: Genome-& AI-Informed Individualized Care of infants in ICUs · Rapid WES NSIGHT2, ClinicalTrials.gov ID NCT03211039. 2019 status of rWGS-based individualized medicine for NICU and](https://reader030.vdocuments.mx/reader030/viewer/2022040313/5e09949b49340d224471f04a/html5/thumbnails/19.jpg)
Step 5: Variant pathogenicity scoring
Richards S, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of ACMG and AMP. Genet Med. 2015 Mar 5.
Very Strong (VS)
Null variant (nonsense, frameshift, ±1 or 2 splice site position, initiation codon, exon deletion) in gene where LOF known to cause disease
Strong (S) • Same amino acid change as previously established pathogenic variant• De novo in a patient with the disease and no family history• Functional studies show damaging effect on the gene• Prevalence in affected individuals significantly greater than controls
Moderate (M)
• Located in mutational hot spot/functional domain without benign variation• Extremely low frequency in Gnomad• Recessive disorders, detected in trans with a pathogenic variant• Protein length changed by in-frame indel in nonrepeat region or stop-loss• Novel missense at amino acid where different missense known to be
pathogenic• Assumed de novo, but without confirmation of paternity and maternity
Supporting (Supp)
• Cosegregation with disease in multiple affected family members in gene known to cause disease
• Missense variant in gene with low rate of benign missense variants and where missense variants commonly cause disease
• Multiple computational tools call deleterious• Phenotype highly specific for disease with single genetic etiology• Reputable source reports as pathogenic, but unpublished
Variant Category Criteria
Pathogenic (P): 99% disease causing
1 VS + (1S or 2M/Sup)2S1S + (3M or 2M+2Supp)
Likely Pathogenic (LP): 90% disease causing
1 VS/S + 1 M1 S + (1 M or 2 Supp)3 M2 M + 2 Supp1 M + 4 Supp
Variant of Uncertain Significance (VUS): 10% disease causing
![Page 20: Genome-& AI-Informed Individualized Care of infants in ICUs · Rapid WES NSIGHT2, ClinicalTrials.gov ID NCT03211039. 2019 status of rWGS-based individualized medicine for NICU and](https://reader030.vdocuments.mx/reader030/viewer/2022040313/5e09949b49340d224471f04a/html5/thumbnails/20.jpg)
125,100,000,000
2,800,000,000
4,872,577
711,870
962
Step 5: Variant Pathogenicity Scoring: 2 mins
Diploid MOON software with InterVar post-processing
Variants present in <1:100 people
Pathogenic and Likely Pathogenic Variants
![Page 21: Genome-& AI-Informed Individualized Care of infants in ICUs · Rapid WES NSIGHT2, ClinicalTrials.gov ID NCT03211039. 2019 status of rWGS-based individualized medicine for NICU and](https://reader030.vdocuments.mx/reader030/viewer/2022040313/5e09949b49340d224471f04a/html5/thumbnails/21.jpg)
• The clinical features of NICU infants do NOT correspond well with classical descriptions of their disease
• The ability to make a diagnosis is critically dependent on a full clinical description
Why collect a deep phenotype
76 children with genetic diseases; natural language processing of EHR; Text book: Mendelian Inheritance in Man
Mean patient phenotypes provided by
MD: 5.0
Mean disease phenotypes in text book: 93.1
Mean patient phenotypes in
EHR: 93.1
Glossary: Phenotype – the clinical features of a patient with a disease
![Page 22: Genome-& AI-Informed Individualized Care of infants in ICUs · Rapid WES NSIGHT2, ClinicalTrials.gov ID NCT03211039. 2019 status of rWGS-based individualized medicine for NICU and](https://reader030.vdocuments.mx/reader030/viewer/2022040313/5e09949b49340d224471f04a/html5/thumbnails/22.jpg)
Step 6: Deep Phenotyping by Natural Language Processing of Epic EMR: 20 sec
CliniThink CLiXENRICH natural language processing software
![Page 23: Genome-& AI-Informed Individualized Care of infants in ICUs · Rapid WES NSIGHT2, ClinicalTrials.gov ID NCT03211039. 2019 status of rWGS-based individualized medicine for NICU and](https://reader030.vdocuments.mx/reader030/viewer/2022040313/5e09949b49340d224471f04a/html5/thumbnails/23.jpg)
Step 7: Translate phenotypes to a hierarchical standardized vocabulary
![Page 24: Genome-& AI-Informed Individualized Care of infants in ICUs · Rapid WES NSIGHT2, ClinicalTrials.gov ID NCT03211039. 2019 status of rWGS-based individualized medicine for NICU and](https://reader030.vdocuments.mx/reader030/viewer/2022040313/5e09949b49340d224471f04a/html5/thumbnails/24.jpg)
Step 8: Pattern Recognition creates a comprehensive differential diagnosis
![Page 25: Genome-& AI-Informed Individualized Care of infants in ICUs · Rapid WES NSIGHT2, ClinicalTrials.gov ID NCT03211039. 2019 status of rWGS-based individualized medicine for NICU and](https://reader030.vdocuments.mx/reader030/viewer/2022040313/5e09949b49340d224471f04a/html5/thumbnails/25.jpg)
125,100,000,000
2,800,000,000
4,872,577
711,870
962 x 159
1
Step 9: Automated Diagnosis: 2 minsManual Diagnosis: 1 – 10 hours
Pathogenic and Likely Pathogenic Variants
Provisional diagnosis
Phenotypes Genetic Diseasesx 14,000
Diploid MOON software with InterVar post-processing
![Page 26: Genome-& AI-Informed Individualized Care of infants in ICUs · Rapid WES NSIGHT2, ClinicalTrials.gov ID NCT03211039. 2019 status of rWGS-based individualized medicine for NICU and](https://reader030.vdocuments.mx/reader030/viewer/2022040313/5e09949b49340d224471f04a/html5/thumbnails/26.jpg)
• X-linked recessive• Inherited from mother• Loss of splice donor site of intron 11• Classified as pathogenic• Confirmed by functional studies
Step 9: Automated Diagnosis: 4 minsManual Diagnosis: 10 hours
![Page 27: Genome-& AI-Informed Individualized Care of infants in ICUs · Rapid WES NSIGHT2, ClinicalTrials.gov ID NCT03211039. 2019 status of rWGS-based individualized medicine for NICU and](https://reader030.vdocuments.mx/reader030/viewer/2022040313/5e09949b49340d224471f04a/html5/thumbnails/27.jpg)
• Diagnosis after 22 hours• Individualized medicine
• Double coverage, double duration antibiotics• Intravenous immunoglobulin to maintain IgG level >600mg/dL• Magnetic resonance imaging: no additional septic emboli
• Prognosis• Normal life• 10% have significant infections despite treatment
• Genetic counseling• Mother is a carrier• Maternal relatives at-risk
• Discharged home on day 13
Hospital Course
Smith and Berglof, Gene Reviews, 2016
![Page 28: Genome-& AI-Informed Individualized Care of infants in ICUs · Rapid WES NSIGHT2, ClinicalTrials.gov ID NCT03211039. 2019 status of rWGS-based individualized medicine for NICU and](https://reader030.vdocuments.mx/reader030/viewer/2022040313/5e09949b49340d224471f04a/html5/thumbnails/28.jpg)
• Retrospective, n=84 children with 86 diagnoses• Expert manual interpretation: Precision 98%, Recall 98%• Automated interpretation: Precision 99%, Recall 95%
Diagnostic performance of 3rd generation rWGS-based individualized medicine
Subject ID 6124 3003Age 14 years 1 year
Abbreviated Presentation
Rhabdo-myolysis
Dystonia, Dev. delay
Method Auto. Auto. Auto. Auto. Auto. Std. Auto. Std. Auto. Std. Auto. Std. Auto. Std. Auto. Std. Auto. Std.Total (hours) 20:25 19:56 19:20 19:14 20:42* 56:03 19:29 48:46 19:11 42:04 19:10 57:21 31:02† 34:38 22:04 38:37 20:53 48:23
Molecular Diagnosis
Glycogen Storage
Disease V
Dopa-Responsive
Dystonia
Gene and Causative Variant(s)
PYGM c.2262delA c.1726C>T
TH c.785C>G c.541C>T
KCNQ2 c.727C>G
INS c.26C>GBTK
c.974+2T>CKCNQ2
c.1051C>Gn.a. n.a. n.a. n.a.
Pseudomonal septic shock
Neonatal seizures
Early Infantile Epileptic
Encephalo-
Permanent neonatal diabetes
X-linked agamma-
globulinemia
Benign familial neonatal
seizures 1NoneNone None None
Neonatal seizures
Hypoglycemia seizures
Pulmonary hemorrhage
Diabetic ketoacidosis
Neonatal seizures
HIE, anemia
17 months 3 days8 days 5 days 3 days 7 weeks 4 weeks 2 days
Retrospective Patients Prospective Patients263 6194 290 352 362 374 7052 412
![Page 29: Genome-& AI-Informed Individualized Care of infants in ICUs · Rapid WES NSIGHT2, ClinicalTrials.gov ID NCT03211039. 2019 status of rWGS-based individualized medicine for NICU and](https://reader030.vdocuments.mx/reader030/viewer/2022040313/5e09949b49340d224471f04a/html5/thumbnails/29.jpg)
• Automated 20-hour diagnosis by rWGS• Lack of clinician familiarity with
individualized medicine• APIs for FAQs, counseling• Case-based learning via podcast/webinar
• Insufficient evidence of efficacy• Cost effectiveness studies• Payor collaborations
• Many genetic diseases lack effectivetreatments
• APIs for reference individualizedmanagement guidance
Summary: Strategies are being implemented to address barriers to rWGS-based individualized medicine for NICU and PICU infants
1%
Use
of r
WG
S in
unD
xN
ICU
, PIC
U in
fant
s
Barriersto
adoption
0% 25%
2012 2018 2021 2025
![Page 30: Genome-& AI-Informed Individualized Care of infants in ICUs · Rapid WES NSIGHT2, ClinicalTrials.gov ID NCT03211039. 2019 status of rWGS-based individualized medicine for NICU and](https://reader030.vdocuments.mx/reader030/viewer/2022040313/5e09949b49340d224471f04a/html5/thumbnails/30.jpg)
Summary: By 2021 we predict the early majority of children’s ICUs to implement individualized medicine
$2.7 Billion
13 years
2003
1st Genome
Nature 460: 1011
1st Medical Genome
$2 Million
1.5 years
2009
Sci. Transl. Med. 4:154ra135
Prototype
$13,00050
hours
2012
Lancet RespirMed. 3:377
EfficacyStudies
2015
$13,00026
hours
EffectivenessStudies
npj Genomic Medicine 3:10
2018
$8,50019
hours
Identifybarriers
Hybrid Effectiveness-Implementation Studies
$5,0001 day
2021
Outcomes:⅓ diagnosed¼ individualized medicine⅕ improved outcomes
![Page 31: Genome-& AI-Informed Individualized Care of infants in ICUs · Rapid WES NSIGHT2, ClinicalTrials.gov ID NCT03211039. 2019 status of rWGS-based individualized medicine for NICU and](https://reader030.vdocuments.mx/reader030/viewer/2022040313/5e09949b49340d224471f04a/html5/thumbnails/31.jpg)
AcknowledgmentsExecutive TeamStephen Kingsmore MD, DScWendy BensonCharlotte Hobbs, MD, PhDDavid Dimmock MDMatt Niedzwiecki
LeadershipShimul Chowdhury PhD,
FACMG, CGMBYan Ding MD, MSKasia Ellsworth PhD, FACMG Lauge Farnaes MD, PhDKaren Garman EdD, MAPPShareef Nahas PhD,
FACMG, CGMBJulie ReinkeGrace SevillaMari Tokita MD Ray Veeraraghavan PhDRussell Nofsinger, PhD
Clinical Genome CenterZaira BezaresJennie Le Maria Ortiz-ArechigaLaura PuckettLuca Van Der KraanCatherine Yamada
Genome AnalystsMichelle Clark PhD Kiely James PhD Terence Wong PhDMeredith Wright PhD
Clinical Trial TeamSara Caylor RN, BSNChristina Clarke RN, BSN Mary Gaughran RN Jerica Lenberg MS, LCGC Lisa Salz MS, LCGC Kelly Watkins MS, LCGC
Clinicians / ResearchersMatthew Bainbridge PhDJeanne Carroll MDTina Chambers PhDMichele Feddock, CCRPJennifer Friedman MDJoseph Gleeson MD, PhDIris ReyesJonathan Sebat PhDNathaly Sweeney MDRobert Wechsler-Reya PhDKristin Wigby MDAmelia Lindgren, MD Erica Sanford, MDKate Perofsky, MD Kathy Bouic Linda Luo Lauren Curley
InternsZia RadyBrandon CampMitch Creed
Information TechnologyJosh BraunSerge BatalovCarlos Diaz Raymond Hovey PhD Dana MashburnPatrick Mulrooney, MAS Danny OhAlbert OriolDorjee Tamang Daniken Orendain
AdministrationAmanda AbbottChristine MoranEllen MontgomeryOlivia SimonidesStacey HuynhSylvia BreedingRachel BurgessJoey Principato Leila SchwanemannCheyenne Camp
Collaboration with:Rady Children’s Hospital UC San Diego HealthScripps Research Translational InstituteNational Institutes of Health• NICHD• NHGRI• NCATSIllumina, Inc.• Haiying Grunenwald• Kevin Hall Alexion• Thomas Defay• John Reynders• Margaret Bray• Paul McDonagh• Brett WilliamsCliniThink• Calum Yacoubian• Alison Frith• Richard GainDiploid• Peter Schols• Cyrielle Kint